Endnote updating pdf index

In this section, as in the 2003 Infection Control Guideline for CF, it is again emphasized that the source of CF pathogens is often unknown and that many individuals with CF are infected with unique strains.However, molecular epidemiology tools have expanded the evidence that people with CF can share epidemic strains of spp.) are also considered.A research agenda is proposed to address some of the unresolved IP&C issues for the CF community, including, for example (1) the role played by small colony variant ; (4) the role played by specific niches for CF pathogens in the natural environment; (5) continued efforts to define best IP&C practices for CF; (6) continued efforts to assess and overcome challenges to implementation of IP&C; and (7) additional research into the unique needs of healthcare personnel with CF.spp., can be transmitted among individuals with CF, resulting in adverse clinical outcomes, including increased morbidity and mortality.

In this section, as in the 2003 Infection Control Guideline for CF, the importance of contact and droplet transmission is emphasized.While the precise routes of transmission are unclear for every acquisition, data support transmission by direct contact with infectious secretions; indirect contact with infectious secretions through contaminated intermediate objects, such as healthcare surfaces, equipment, or the hands of healthcare personnel; and/or infectious droplets.New data are provided demonstrating that droplets can travel as far as 6 feet (2 meters), the complexities of droplet transmission are described, and the potential role played by droplet nuclei in transmission of CF pathogens is discussed.Successful and consistent implementation of IP&C practices must include the ongoing participation of people with CF and their families as well as auditing the IP&C practices of healthcare personnel and feedback about their performance., while recognizing that the risk is unlikely to reach zero.

Leave a Reply